Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX
Cumberland Pharmaceuticals — Parent Project Muscular Dystrophy Annual Conference (June 2026)
8 slides from Cumberland Pharmaceuticals's conference presentation, Jun 26, 2026
Slide 1: The FIGHT DMD Trial: Cardiac Findings with Ifetroban in Duchenne Muscular Dystrophy
The FIGHT DMD Trial: June 26, 2026 Cardiac Findings with Ifetroban in Duchenne Muscular Dystrophy Chet R. Villa, MD Professor, Department of Pediatrics University of Cincinnati Pediatric Cardiologist Cincinnati Children’s Hospital
Slide 2: Disclosure
Disclosure • Site Principal Investigator for the FIGHT DMD trial, sponsored by Cumberland Pharmaceuticals • Presentation content prepared in collaboration with Cumberland Pharmaceuticals. PPMD Conference
Slide 3: How Ifetroban Works
How Ifetroban Works ▪ Ifetroban blocks some of the damage Calcium overload signals that lead to heart muscle in heart cells injury in DMD ▪ Less cell damage means less fibrosis Ifetroban and less loss of heart function over time ▪ Safety established in over 1,400 clinical trial participants across n
Slide 4: FIGHT DMD Study Design and Open-Label Extension
FIGHT DMD Study Design and Open-Label Extension Planned enrollment of 48 boys; final enrollment was 41 randomized across the three arms STUDY DESIGN • All subjects received high dose ifetroban (300 mg/day) • 21 subjects have completed up through 36 months with some completing 48 months of treatment
Slide 5: Cardiac Efficacy after 12 Months of Treatment
Cardiac Efficacy after 12 Months of Treatment Heart Pumping Blood Marker of Heart Strain and Damage Increased with High-dose Ifetroban Decreased with High-dose Ifetroban 5.4% Improvement in left 54 pg/mL Average Reduction ventricular ejection fraction in NT-proBNP (p = 0.002) (p = 0.017) N = 12 high
Slide 6: Blood Biomarkers Reflect Cardiac Improvement Over 12 Months of Treatment
Blood Biomarkers Reflect Cardiac Improvement Over 12 Months of Treatment These blood proteins changed in directions consistent with heart muscle protection, supporting the cardiac function results Markers of Protection and Repair Markers of Cell Damage Increased with High-dose Ifetroban* Reduced wit
Slide 7: Safety Profile of Ifetroban
Safety Profile of Ifetroban • Most reported adverse events related to underlying disease • No serious adverse events (SAEs) deemed related to study medication • Events possibly related to ifetroban: bruising (2 high-dose, 1 low-dose), and small broken blood vessels (1 high-dose) • Ifetroban used saf
Slide 8: Program Next Steps
Program Next Steps February 2025 February 2026 August 2026 FIGHT DMD Fast Track Long-term safety Topline results Designation and efficacy data announced granted expected through M36 Ifetroban has received Rare Pediatric Disease, Orphan Drug and Fast Track Designations PPMD Conference
Cumberland Pharmaceuticals — Parent Project Muscular Dystrophy Annual Conference (June 2026) on 6ix